{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T04:26:14Z","timestamp":1763526374492,"version":"3.45.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"DOI":"10.7759\/cureus.97186","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T04:23:31Z","timestamp":1763526211000},"source":"Crossref","is-referenced-by-count":0,"title":["Vonoprazan Therapy in Gastroesophageal Reflux Disease (GERD): Effects on the Severity and Frequency of GERD in Relation to Hiatus Hernia"],"prefix":"10.7759","author":[{"given":"Adnan","family":"Ur Rehman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Shoaib","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Iltaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiqas","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naeem","family":"Jan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06141-5","article-title":"Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis","volume":"66","author":"Cheng Y","year":"2021","unstructured":"Cheng Y, Liu J, Tan X, et al.. Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis. Dig Dis Sci. 2021, 66:19-28. 10.1007\/s10620-020-06141-5","journal-title":"Dig Dis Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019520","article-title":"Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease","volume":"99","author":"Gotoh Y","year":"2020","unstructured":"Gotoh Y, Ishibashi E, Honda S, Nakaya T, Noguchi C, Kagawa K, Murakami K. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease. Medicine (Baltimore). 2020, 99:e19520. 10.1097\/MD.0000000000019520","journal-title":"Medicine (Baltimore)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-022-01861-z","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021","volume":"57","author":"Iwakiri K","year":"2022","unstructured":"Iwakiri K, Fujiwara Y, Manabe N, et al.. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022, 57:267-85. 10.1007\/s00535-022-01861-z","journal-title":"J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050699","article-title":"Advances in gastroesophageal reflux disease management: exploring the role of potassium-competitive acid blockers and novel therapies","volume":"18","author":"Hossa K","year":"2025","unstructured":"Hossa K, Ma\u0142ecka-Wojciesko E. Advances in gastroesophageal reflux disease management: exploring the role of potassium-competitive acid blockers and novel therapies. Pharmaceuticals (Basel). 2025, 18:10.3390\/ph18050699","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07760-9","article-title":"Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms","volume":"24","author":"Wang D","year":"2023","unstructured":"Wang D, Zhou D, Liu X, Xu Z, Bai T, Hou X. Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms. Trials. 2023, 24:778. 10.1186\/s13063-023-07760-9","journal-title":"Trials"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0165","article-title":"Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis","volume":"12","author":"He J","year":"2023","unstructured":"He J, Gao Y, Bai G, Wang J, Sun Y. Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis. J Comp Eff Res. 2023, 12:e220165. 10.57264\/cer-2022-0165","journal-title":"J Comp Eff Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.05.004","article-title":"Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial","volume":"22","author":"Laine L","year":"2024","unstructured":"Laine L, Spechler S, Yadlapati R, et al.. Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial. Clin Gastroenterol Hepatol. 2024, 22:2211-2220.e10. 10.1016\/j.cgh.2024.05.004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000101","article-title":"Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study","volume":"10","author":"Kinoshita Y","year":"2019","unstructured":"Kinoshita Y, Sakurai Y, Takabayashi N, et al.. Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study. Clin Transl Gastroenterol. 2019, 10:e00101. 10.14309\/ctg.0000000000000101","journal-title":"Clin Transl Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial","volume":"164","author":"Laine L","year":"2023","unstructured":"Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology. 2023, 164:61-71. 10.1053\/j.gastro.2022.09.041","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21608\/ijma.2023.189701.1607","article-title":"Comparative study between the efficacies of vonoprazan versus omeprazole in patients with gastroesophageal reflux disease","volume":"5","author":"Mahdi MAE","year":"2023","unstructured":"Mahdi MAE, Al-Zhaby AAA-E, Abdel-Halim MM, Hassan MA. Comparative study between the efficacies of vonoprazan versus omeprazole in patients with gastroesophageal reflux disease. Int J Med Arts. 2023, 5:2958-66. 10.21608\/ijma.2023.189701.1607","journal-title":"Int J Med Arts"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01572-y","article-title":"Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease","volume":"54","author":"Miwa H","year":"2019","unstructured":"Miwa H, Igarashi A, Teng L, Uda A, Deguchi H, Tango T. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. J Gastroenterol. 2019, 54:718-29. 10.1007\/s00535-019-01572-y","journal-title":"J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17728","article-title":"Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease","volume":"58","author":"Fass R","year":"2023","unstructured":"Fass R, Vaezi M, Sharma P, et al.. Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease. Aliment Pharmacol Ther. 2023, 58:1016-27. 10.1111\/apt.17728","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18458","article-title":"Integrated analysis of vonoprazan safety for symptomatic gastro-oesophageal reflux disease or erosive oesophagitis","volume":"61","author":"Howden CW","year":"2025","unstructured":"Howden CW, Katz P, DeVault KR, et al.. Integrated analysis of vonoprazan safety for symptomatic gastro-oesophageal reflux disease or erosive oesophagitis. Aliment Pharmacol Ther. 2025, 61:835-51. 10.1111\/apt.18458","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02193-x","article-title":"Vonoprazan: a review in erosive esophagitis and non-erosive gastro-esophageal reflux disease","volume":"85","author":"Fung S","year":"2025","unstructured":"Fung S. Vonoprazan: a review in erosive esophagitis and non-erosive gastro-esophageal reflux disease. Drugs. 2025, 85:945-55. 10.1007\/s40265-025-02193-x","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2024.2355351","article-title":"The presence of hiatal hernia is a significant predictor for symptomatic recurrence after cessation of vonoprazan therapy for gastroesophageal reflux disease: a long-term observational study","volume":"59","author":"Shinozaki S","year":"2024","unstructured":"Shinozaki S, Osawa H, Miura Y, et al.. The presence of hiatal hernia is a significant predictor for symptomatic recurrence after cessation of vonoprazan therapy for gastroesophageal reflux disease: a long-term observational study. Scand J Gastroenterol. 2024, 59:893-9. 10.1080\/00365521.2024.2355351","journal-title":"Scand J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/grp\/5620034","article-title":"Efficacy of step-down therapy using vonoprazan for symptomatic mild reflux esophagitis","volume":"2024","author":"Ochiai Y","year":"2024","unstructured":"Ochiai Y, Kikuchi D, Hoteya S. Efficacy of step-down therapy using vonoprazan for symptomatic mild reflux esophagitis. Gastroenterol Res Pract. 2024, 2024:5620034. 10.1155\/grp\/5620034","journal-title":"Gastroenterol Res Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14468","article-title":"Randomized clinical trial: a double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40\u2009mg versus esomeprazole 40\u2009mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor","volume":"35","author":"Tack J","year":"2023","unstructured":"Tack J, Vladimirov B, Horny I, Chong CF, Eisner J, Czerniak R, Takanami Y. Randomized clinical trial: a double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40\u2009mg versus esomeprazole 40\u2009mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor. Neurogastroenterol Motil. 2023, 35:e14468. 10.1111\/nmo.14468","journal-title":"Neurogastroenterol Motil"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000858200.17525.4a","article-title":"S390 efficacy and safety of on-demand vonoprazan versus placebo in the treatment of heartburn in symptomatic nonerosive reflux disease (NERD) patients: a phase 2 randomized controlled trial","volume":"117","author":"Fass R","year":"2022","unstructured":"Fass R, Vaezi MF, Sharma P, et al.. S390 efficacy and safety of on-demand vonoprazan versus placebo in the treatment of heartburn in symptomatic nonerosive reflux disease (NERD) patients: a phase 2 randomized controlled trial. Off J Am Coll Gastroenterol ACG. 2022, 117:272-3. 10.14309\/01.ajg.0000858200.17525.4a","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2024.10.008","article-title":"American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations","volume":"101","author":"Desai M","year":"2025","unstructured":"Desai M, Ruan W, Thosani NC, et al.. American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations. Gastrointest Endosc. 2025, 101:267-84. 10.1016\/j.gie.2024.10.008","journal-title":"Gastrointest Endosc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64777","article-title":"A comprehensive review on the efficacy and safety of vonoprazan in the management of gastric acid-related diseases","volume":"16","author":"Padwale V","year":"2024","unstructured":"Padwale V, Kirnake V, Daswani R, Kodmalwar A, Gupta A. A comprehensive review on the efficacy and safety of vonoprazan in the management of gastric acid-related diseases. Cureus. 2024, 16:e64777. 10.7759\/cureus.64777","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003140","article-title":"The Role of P-CABs in GERD","volume":"120","author":"Howden CW","year":"2025","unstructured":"Howden CW. The Role of P-CABs in GERD. Am J Gastroenterol. 2025, 120:993-8. 10.14309\/ajg.0000000000003140","journal-title":"Am J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16475","article-title":"A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease","volume":"39","author":"Simadibrata DM","year":"2024","unstructured":"Simadibrata DM, Lesmana E, Fass R. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease. J Gastroenterol Hepatol. 2024, 39:796-805. 10.1111\/jgh.16475","journal-title":"J Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.06.038","article-title":"AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review","volume":"167","author":"Patel A","year":"2024","unstructured":"Patel A, Laine L, Moayyedi P, Wu J. AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review. Gastroenterology. 2024, 167:1228-38. 10.1053\/j.gastro.2024.06.038","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.252","article-title":"CO166 patient reported outcomes of vonoprazan in Chinese reflux esophagitis patients: a prospective real-world study","volume":"27","author":"Xiao Y","year":"2024","unstructured":"Xiao Y, Xue Z, Zhang Z, Nail A, Song Q, Xie L, Chen M. CO166 patient reported outcomes of vonoprazan in Chinese reflux esophagitis patients: a prospective real-world study. Value Heal. 2024, 27:48. 10.1016\/j.jval.2024.03.252","journal-title":"Value Heal"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430617-vonoprazan-therapy-in-gastroesophageal-reflux-disease-gerd-effects-on-the-severity-and-frequency-of-gerd-in-relation-to-hiatus-hernia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T04:23:34Z","timestamp":1763526214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430617-vonoprazan-therapy-in-gastroesophageal-reflux-disease-gerd-effects-on-the-severity-and-frequency-of-gerd-in-relation-to-hiatus-hernia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.97186","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}